TARO PHARMACEUTICALS U.S.A., INC.

Orexo will host a seminar at Nordic Life Science Days on October 13 to share insights from its recent patent victory against Sun Pharmaceutical Industries in December 2024.

Sun Pharmaceutical Industries announced that tildrakizumab (ILUMYA) 100 mg successfully met primary endpoints in two Phase 3 clinical studies for active psoriatic arthritis treatment.

Sun Pharma's European biotech partner Philogen voluntarily withdrew the marketing authorization application for Nidlegy, an investigational melanoma therapy, from the European Medicines Agency.

Kirti Ganorkar, a 29-year Sun Pharma veteran, will become Managing Director on September 1, 2025, succeeding founder Dilip Shanghvi who transitions to Executive Chairman.

India launches the ₹5,000 crore Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme, expected to attract ₹17,000 crore in additional R&D investment by end of 2025.

Sun Pharmaceutical Industries has gained significant legal leverage after a US Court of Appeals vacated a preliminary injunction against its alopecia areata treatment Leqselvi, potentially enabling commercialization despite ongoing litigation with Incyte.

Sun Pharma is developing a promising obesity treatment GL0034, which demonstrated significant weight loss and metabolic improvements in Phase 1 trials.

• Mankind Pharma has developed a pioneering GPR109 agonist as the world's first potential small-molecule oral treatment for obesity, currently advancing through Phase 2 trials in Australia. • The innovative drug offers advantages over existing injectable peptide treatments like Wegovy and Mounjaro, requiring no food-related restrictions and providing a more convenient oral administration route. • Phase 1 results have shown promising outcomes, with Phase 2 trial results expected by the end of the year, positioning Mankind Pharma for a potential breakthrough in the global obesity treatment market.

Sezaby, a preservative-free phenobarbital formulation by Sun Pharmaceutical Industries, has been approved as the first FDA-sanctioned treatment specifically for neonatal seizures in both term and preterm infants.

The global basal cell carcinoma market is projected to grow from $5.48 billion in 2024 to $9.7 billion by 2035, exhibiting a CAGR of 5.34% according to IMARC Group research.